<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36172860</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8301</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>32</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Future oncology (London, England)</Title><ISOAbbreviation>Future Oncol</ISOAbbreviation></Journal><ArticleTitle>Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre.</ArticleTitle><Pagination><StartPage>3585</StartPage><EndPage>3594</EndPage><MedlinePgn>3585-3594</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2022-0088</ELocationID><Abstract><AbstractText><b>Background:</b> Few studies have investigated the long-term effects of COVID-19 on cancer patients. <b>Materials &amp; methods:</b> The authors conducted a telephone survey on the long-term symptoms of cancer patients from Guy's Cancer Centre. They compared patients whose symptoms occurred/got worse over 4 weeks after COVID-19 diagnosis (classified as&#xa0;long COVID) with patients who did not develop symptoms or whose symptoms occurred/got worse in the first 4 weeks after diagnosis. <b>Results:</b> The authors analyzed responses from 80 patients with a previous COVID-19 diagnosis; 51.3% (n&#xa0;=&#xa0;41) developed long COVID. The most common symptoms were fatigue, breathlessness and cognitive impairment. <b>Conclusion:</b> Findings suggest that over half of the cancer population will experience long-term effects after their initial COVID-19 diagnosis. Further studies are required to validate the findings of this study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monroy-Iglesias</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-2417-3275</Identifier><AffiliationInfo><Affiliation>King's College London, School of Cancer &amp; Pharmaceutical Sciences, Translational Oncology &amp; Urology Research (TOUR), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremble</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's &amp; St. Thomas' NHS Foundation Trust (GSTT), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>King's College London, School of Cancer &amp; Pharmaceutical Sciences, Translational Oncology &amp; Urology Research (TOUR), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4354-8987</Identifier><AffiliationInfo><Affiliation>King's College London, School of Cancer &amp; Pharmaceutical Sciences, Translational Oncology &amp; Urology Research (TOUR), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolly</LastName><ForeName>Saoirse</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's &amp; St. Thomas' NHS Foundation Trust (GSTT), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sita-Lumsden</LastName><ForeName>Ailsa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's &amp; St. Thomas' NHS Foundation Trust (GSTT), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortellini</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cancer, Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, W120HS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinato</LastName><ForeName>David James</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Cancer, Department of Surgery &amp; Cancer, Imperial College London, Hammersmith Hospital, London, W120HS, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigg</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's &amp; St. Thomas' NHS Foundation Trust (GSTT), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karagiannis</LastName><ForeName>Sophia N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>St. John's Institute of Dermatology, School of Basic &amp; Medical Biosciences, King's College London, London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hemelrijck</LastName><ForeName>Mieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>King's College London, School of Cancer &amp; Pharmaceutical Sciences, Translational Oncology &amp; Urology Research (TOUR), London, SE1 9RT, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L023091/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Oncol</MedlineTA><NlmUniqueID>101256629</NlmUniqueID><ISSNLinking>1479-6694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">oncology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>29</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36172860</ArticleId><ArticleId IdType="doi">10.2217/fon-2022-0088</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>